Onxeo : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at November 30, 2014

PARIS--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News :

Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO) :

Pursuant to article L.233-8 II of the Code de commerce (the French Commercial
Code) and article 223-16 of the Règlement général de l’Autorité des Marchés
Financiers (Regulation of the French stock market authority):

Date         Total number of     Total number of voting rights
             outstanding
             shares
November     31, 490, 644        Theoretical number of voting rights: 31, 490,
30, 2014                         644
                                 (including treasury shares)Number of real
                                 voting rights: 31, 461,991(without treasury
                                 shares)

About Onxeo
Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives to “make the difference”. The Onxeo teams are determined to develop
innovative medicines to provide patients with hope and significantly improve
their lives.
Key products at advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Positive preliminary results of the Phase II
trial in severe oral mucositis
Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma
For more information, visit the
website www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3
A 
%2F%2Fwww.onxeo.com&esheet=50995578&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=1&md5=54a6868e4600478b968544f7c5705c17)
CONTACT:

Onxeo
Judith Greciet, CEO
j.greciet@onxeo.com
or
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Alize RP
Caroline Carmagnol / Sophie Colin, +33 6 64 18 99 59 / +33 1 44 54 36 62
caroline@alizerp.com / scolin@alizerp.com